Form 4: Prothena Corp Public Ltd Co: Executive Acquires Stock Options

Chad J. Swanson, Chief Development Officer of Prothena Corp Public Ltd Co, acquired stock options for 107,500 ordinary shares on March 5, 2025.

Summary

• On March 5, 2025, Chad J. Swanson, the Chief Development Officer of Prothena Corp Public Ltd Co, was granted stock options.
• These options give him the right to purchase 107,500 ordinary shares at an exercise price of $14.95 per share.
• The options vest over a four-year period, with 25% vesting on March 5, 2026, and the remaining 75% vesting in equal monthly installments thereafter, contingent upon continued employment.
• The options expire on March 5, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral-positive event.

Positives

• The grant of stock options aligns the executive's interests with those of the shareholders, incentivizing him to contribute to the company's long-term success.

Future Outlook

The vesting schedule suggests a commitment from the executive to remain with the company for at least four years.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in biotech companies like Prothena.
• Companies such as Biogen, Amgen, and Gilead Sciences also utilize stock options to incentivize their leadership teams.
• The vesting schedule and exercise price are typical for such grants, designed to reward long-term performance and commitment.

Stakeholder Impact

• Shareholders may view the stock option grant positively, as it incentivizes the executive to increase shareholder value.
• Employees may see it as a sign of the company's commitment to its leadership team.

Key Dates